The breast cancer protocol information is intended for use by a healthcare professional. If you have questions about a referral, please contact your provider.
Select Study Type
- Phase I Studies
- Prevention/Early Detection
- Treatment
- Primary
- High Risk
- Metastatic
- Side Effect Management - NCI Sponsored Trials
- Susan G. Komen Sponsored Trials
If after reviewing your clinical information, you are found to be a candidate for a clinical trial at the Arizona Cancer Center, an appointment can be made for your evaluation.
If you live in one of the communities that is a site for the Arizona Telemedicine Program, this initial appointment may be made via teleconferencing. You and your provider would be able to interact directly with a medical oncologist at the Arizona Cancer Center and discuss your condition.
Phase I Studies
| Eligibility: Thank you for your interest in Phase I Studies. Phase I studies are the first step in the clinical trial process. People who are eligible for phase I studies are not eligible for standard therapy. If your provider feels you are in this category please request specific information by clicking the link below. |
| Referral Form |
| For more information, please click on
Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
| An Open Label, Dose Escalation Study to Determine the Maximum Tolerated Dose and to Evaluate the Safety Profile of CC-5513 with Weekly Docetaxel (Taxotere ®) |
| Eligibility: Subjects with Advanced Solid Tumors |
| Treatment: Docetaxel is a standard therapy for many tumors and given every week in the vein. CC-5013 is an experimental therapy given every day by mouth for 21 days in a row along with the docetaxel. The study drug, CC-5013, will be supplied free of charge by Celgene corporation. |
| Referral Form |
| For more information, please click on
Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
Prevention/Early Detection
| Study of tamoxifen and raloxifene (STAR) for the Prevention of Breast Cancer |
HSC 99-93 |
| Eligibility: Patient must be at high risk for developing breast cancer and must not have had prior tamoxifen, raloxifene or other selective estrogen receptor modulator treatment. | |
| Treatment: I: Tamoxifen II: Raloxifene | |
| Referral Form | |
| For more information, please
click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. | |
Treatment
Primary
| C49907: A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC), Versus Capecitabine in Women 65 years and Older with Node Positive or High-Risk Node Negative Breast Cancer |
| Eligibility: Must be 65 years or older with early stage
tumor removed by modified radical mastectomy or a lumpectomy. Patients must
have had either an axillary node dissection or sentinel lymph node biopsy before
beginning this treatment. Less than 84 days from mastectomy or within 84 days of axillary dissection if patient's most extensive breast surgery was a breast sparing procedure. |
| Treatment: Patient will be randomized
to one of these two arms: Arm A: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC) Arm B: Capecitabine |
|
For more information, please click on
Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
| CALGB/SWOG 40101: Cyclophosphamide and Doxorubicin (CA) (4 versus 6 cycles) versus Paclitaxel (12 weeks versus 18 weeks) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study. |
|
Eligibility: Histologically confirmed adenocarcinoma of the female breast and negative lymph nodes determined by either an axillary node dissection or a positive sentinel node finding by H&E, with clear margins. Less than 84 days from mastectomy or from axillary dissection or sentinel node detection if the patient’s most extensive breast surgery was a breast sparing procedure. Treatment: Patients will be randomized to one of three arms: Arm I: AC q 2 weeks for 4 cycles (60/600) Arm II: AC q 2 weeks for 6 cycles (60/600) Arm III: Paclitaxel q 2 weeks for 12 weeks (80) Arm IV: Paclitaxel q 2 weeks for 18 weeks (80) |
|
For more information, please
click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
|
B-35: A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy. |
|
Eligibility: Histologic examination the tumor must be ductal carcinoma in situ (DCIS) and be ER/PR positive as confirmed by IHC. Margins must be clear and any node dissection (if done) must be pathologically negative. Less than 84 days from lumpectomy or re-excision of lumpectomy margins to the randomization of this trial. Treatment: Patients will be randomized to two treatment arms: Group 1: Tamoxifen (20mg) and placebo (daily) x 5 years + Breast Radiation Therapy Group 2: Anastrozole (1mg) and placebo (daily) x 5 years + Breast Radiation Therapy For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
High Risk |
| Study of tamoxifen and raloxifene (STAR) for the Prevention of Breast Cancer |
HSC 99-93 |
| Eligibility: Patient must be at high risk for developing breast cancer and must not have had prior tamoxifen, raloxifene or other selective estrogen receptor modulator treatment. | |
| Treatment: I: Tamoxifen II: Raloxifene | |
| Referral Form | |
| For more information, please
click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
|
|
Node-Positive or High-Risk Node Negative Dose Dense |
SWOG 0221 |
|
Phase III Trial of Continuous Schedule AC + G vs. Q 2 week Schedule AC followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post Operative Adjuvant Therapy in Node-Positive or High Risk Node Negative Breast CancerEligibility: High Risk: Histologically confirmed Diagnosis of operable Stage I, II or III invasive breast carcinoma with known estrogen and progesterone receptor status. Tumor ~ 2 cm &/or one or more axillary or intramammary nodes involved. Less than 84 days from final surgical procedure. Treatment: Arm I: AC + PEG-G q 2 weeks x 6 cycles; T + PEG-G q 2 weeks x 6 cycles Arm II: AC + G x 15 weeks; T + PEG-G q 2 weeks x 6 cycles Arm III: AC + PEG-G q 2 weeks x 6 cycles; weekly T x 12 weeks Arm IV: AC + G x 15 weeks; weekly T x 12 weeks For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you.
|
|
|
Better Than Ever Study for Women at High Risk for Breast Cancer |
|
|
Eligibility: Twenty women who are at high risk of developing breast cancer based on the Gail model, women with a BRCA mutation or women with a previously diagnosed breast cancer will be enrolled into the study. High risk women are evaluated through the High Risk Breast Cancer Clinic. Evaluation will include a complete clinical history, physical examination and a screening mammogram, ultrasound or MRL. High risk women on the basis of at least one of the following:
Treatment: Subjects will be pre-selected based on successful identification of NAF secreting ducts. Suction aspiration will be applied to identify the secreting ducts. If NAF is found, patients will be scheduled for breast endoscopy. Breast endoscopies are performed in the AZCC clinics initially and repeated at 6 months. NAF, lavage fluid, and ductoscopic biopsy (if obtained) are collected and processed for pathology, karyometry, and microarray methylation analysis. For more information, please click on Protocol QuestionsNote: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
|
Metastatic
|
|
Phase II Trial of Imatinib Mesylate (Gleevec) in Combination with Capecitabine (Xeloda) in Metastatic Breast Cancer |
SWOG 0338 Temporary Closure |
|
Eligibility: Patients must have histologically or cytologically Stage IV adenocarcinoma of the breast. Patients must have progressed on at least one but no more than two prior chemotherapy regimens for metastatic disease. Patients must have measurable disease. Treatment: Gleevec 400mg* p.o. (daily) + Capecitabine 1,OOOmg/m2 p.o. bid (days 1-14) * if patients tolerates the starting dose of Gleevec (400mg) it will be increased to 600mg/day For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you.
|
|
Side Effect Management |
|
Massage Treatment in Breast Cancer-Related Lymphedema |
|
Eligibility: Patients with mild breast cancer-related lymphedema would potentially be eligible for this study. Treatment: Patients will be randomly assigned to either massage alone or massage with bandaging treatment. Participant’s arms will be measured by study personnel and participants will complete a short questionnaire at the beginning of the study, at the end of a two week treatment period (10 sessions) and at a six-month follow up visit. For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals and patients about the breast cancer-related lympheclinical trial only. Thank you.
|
|
Green Tea Intervention for Weight Gain Prevention among Women with Breast Cancer |
|
Eligibility: postmenopausal, Stage I, II, or IIIa invasive breast cancer, has completed chemotherapy in past 1 - 4 weeks and gained> 2 kg during treatment. No prior tamoxifen treatment, no current dietary supplements with tea or tea extracts. Not on weight loss medications or in weight loss program. Treatment: Patients will be randomly assigned to either Green Tea or Placebo Tea for 12 months. Body measurements, resting metabolic rate, blood and urine samples, and cognitive tests will be completed at baseline, 6 months and 12 months. Food, tea, exercise, demographic, and quality of life questionnaires will also be completed. For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you.
|
| SHINE CARES Chemotherapy and Radiation Effects |
|
Eligibility: SHINE CARES is currently recruiting women between the ages of and 75 who have been diagnosed with Stage I, Stage 2, or Stage 3 breast cancer two or more years ago, and have received local therapy and/or chemotherapy. Treatment: Study participants will answer questions about their breast cancer and medical history; complete questionnaires about coping, personality, mood, and memory; have an MRI scan (a safe way to take pictures of the brain and its structures); and complete an assessment of memory and other skills. For more information, please click on Protocol Questions Note: This email contact is for specific questions from healthcare professionals about breast cancer clinical trials only. If you are a patient seeking advice on a health matter, please contact your health care provider directly. Thank you. |
We Need Your Help!
The National Cancer Institute (NCI) is developing new education materials to address concerns that people with cancer and their families face throughout the course of the disease. We need to know what you believe is important to include in these materials. We are looking for:
- Patients: Who have recurrent or Stage III or Stage IV cancer
- Current informal caregivers: Family or friends who are currently providing care for someone in treatment for cancer
- Bereaved informal caregivers: Family members or friends who have provided care at end of life for someone who died from cancer within the last 2 years
- Physicians: Who work with people with advanced cancer.
We will be conducting individual telephone interviews with patients and telephone focus group discussions with informal caregivers and health professionals to learn about your experiences with cancer. Payment will be provided to all participants.
Please call us toll-free at:
1-888-249-0029
We will ask a few questions to see if you qualify to participate. If you qualify, you will be contacted at a later date for scheduling.
We Need Your Help!
The National Cancer Institute (NCI) is developing new education materials in Spanish to address concerns that people with cancer and their families face throughout the course of the disease. We need to know what you believe is important to include in these materials. We are looking for:
-
Family or friends who are currently providing care for someone in treatment for cancer
-
Family members or friends who have provided care at end of life for someone who died from cancer within the last 2 years
We will be conducting telephone focus group discussions in Spanish to learn about your experiences with cancer. Payment will be provided to all participants.
Please call us toll-free at:
1-888-249-0029
We will ask a few questions to see if you qualify to participate. If you qualify, you will be contacted at a later date for scheduling.
¡Necesitamos su ayuda!
El Instituto Nacional del Cáncer (National Cancer Institute o NCI) está elaborando unos nuevos materiales en español para hacer frente a las preocupaciones que tienen las personas con cáncer y sus familias. Queremos saber su opinión acerca de lo que usted considera que sea importante incluir en estos materiales. Buscamos:
-
Familiares o amigos quienes actualmente están proporcionando cuidados a alguien que está recibiendo tratamiento para el cáncer
-
Familiares o amigos quienes hayan proporcionado cuidados de hospicio a alguien con cáncer que murió en los últimos dos años
Para enterarnos de sus experiencias con el cáncer, vamos a llevar a cabo algunos grupos de enfoque en forma de conversaciones por teléfono. Todos los participantes recibirán un pago.
Por favor, llámenos gratis al: